{"name":"Xinjiang Biochemical Pharmaceutical Co., Ltd.","slug":"xinjiang-biochemical-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"","description":"Xinjiang Biochemical Pharmaceutical Co., Ltd. is a pharmaceutical company based in Xinjiang, China, with a focus on developing and marketing specialized drug products. The company's primary marketed product is Gastropylor Complex Capsules, which targets gastrointestinal disorders.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Gastropylor Complex Capsules","genericName":"Gastropylor Complex Capsules","slug":"gastropylor-complex-capsules","indication":"Gastric motility disorders","status":"marketed"}]}],"pipeline":[{"name":"Gastropylor Complex Capsules","genericName":"Gastropylor Complex Capsules","slug":"gastropylor-complex-capsules","phase":"marketed","mechanism":"Gastropylor Complex Capsules is a herbal/botanical combination formulation designed to support gastric motility and digestive function.","indications":["Gastric motility disorders","Dyspepsia and digestive symptoms"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNYnA1ZUhySjhMNHZOei1rVExGaU9kYnVMZlBCRVNPVUwxdVd2ZTZYSXZzU3hCM1ZXck1FWWZpOF95NlFxWENOOTEwLVRPcWhaOG5qYXFaX2FnQktXZWhWRFE0WGVOaDRTQXZZR2lEMnI2N2hIYjV0a3pHeDQxaEFVQjlUNFM2RnRsTmF1ZUN1N3hXNlVKdnIzZ0t1bFNNSzRpcmZQRXVobXpXamp5MExjTm9rTQ?oc=5","date":"2024-05-13","type":"pipeline","source":"Kharon","summary":"Pharmaceutical and Biotech Industry Faces Possible Exposure to Xinjiang Forced Labor - Kharon","headline":"Pharmaceutical and Biotech Industry Faces Possible Exposure to Xinjiang Forced Labor","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}